Dr. Laubach on the Efficacy of Daratumumab in Myeloma

Jacob Laubach, MD, MPP
Published Online: Monday, December 9, 2013


Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute and an Instructor in Medicine at the Harvard Medical School, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

At doses of 4 mg/kg or higher, the overall response rate, including minimal response, was over 60%, Laubach states. Additionally, the rate of partial response or better was in the range of 40% to 45%, as defined as a 50% reduction in monoclonal protein.

In general, daratumumab was well tolerated. As expected, infusion reactions were observed, specifically early on in the trial. The leading infusion reaction was bronchospasm, Laubach notes. In general, the early administration of supportive medications, such as corticosteroids, seems to help alleviate some of these conditions, making the drug overall well tolerated.

<<< View more from the 2013 ASH Meeting

Online CME Activities
Free CME from PER
31st Annual Miami Breast Cancer Conference® Clinical Vignette Series
Clinical Vignettes Series: Hematologic Malignancies
Miami Lung Cancer Conference™ Medical Crossfire®
Community Practice Connections: 18th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
More Reading
Publications
$auto_registration$